anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The study experimentally tested an intervention that debunks epistemically suspect beliefs about vaccines. After answering questions about pre-existing epistemically suspect beliefs (irrational health beliefs and conspiracy mentality), 565 participants were randomly assigned into one of three conditions and exposed either to neutral information about domestic animals, salient epistemically suspect content about vaccination or an intervention that debunks epistemically suspect beliefs about vaccination. Afterwards, the participants answered questions about vaccination-related conspiracy narratives (manipulation check), vaccination attitudes, intentions to vaccinate against HPV, support for an HPV vaccination programme and intentions to seek health guidance. Although the intervention demonstrated the potential to inhibit the endorsement of conspiracy narratives, we found no differences in the other outcome variables. Nevertheless, across the conditions, pre-existing epistemically suspect beliefs were associated with less favourable attitudes towards vaccination, lower intentions to vaccinate against HPV, less support for the vaccination programme and lower intentions to seek health guidance. The results indicate that debunking may be futile in curbing long-term negative impacts associated with epistemically suspect beliefs, and they contribute to the debate about assessing the effectiveness of interventions related to highly controversial topics such as vaccination. The study enhances understanding of persistent adverse impacts that epistemically suspect beliefs may have on public health outcomes.
PURPOSE: To provide an unstimulant oral compsn. having high foaming property by compounding an effective amt. of highly purified sodium lauryl sulfoacetate surfactant. CONSTITUTION: This oral compsn. contains an effective amt. of purified sodium lauryl sulfoacetate prepared in such a manner that the proportion of sodium salt except for dodecylsulfoacetate as an impurity is controlled in <18 wt.%, and the compsn. has high foaming property, and is not stimulating. The purified sodium lauryl sulfoacetate is preferably compounded by about 0.5 to 5.0 wt.%. To enhance the foaming power and unstimulating property of the surfactant, a nonionic or amphoteric compd. is preferably compounded. As for the nonionic compd., for example, polyoxy-ethylene monoester of sorbitol is used, and as for the amphoteric compd. for example, cocoamido propylbetaine can be used. Further, a nonionic antimicrobial agent may be compounded by about 0.05 to 1%.
A total of 60 subject will be recruited among patients seeking periodontal treatment at the Department. All subjects will have periodontitis diagnosed according to the criteria outlined in the 2017 Classification of Periodontal and Peri-implant Diseases and Conditions. The subjects will be divided into two groups based on smoking status. The first group of 30 subjects will consist of cigarettes smokers and the second group of 30 non- smokers. All the subjects in the first group smoke for a minimum of 3 years and at least 10 cigarettes a day. Patients smoking e-cigarettes, tobacco heating systems, cigarettes without filter and occasional smokers will be excluded from the study. Moreover, minors, pregnant woman, patients with systemic diseases affecting periodontal tissues, immunodeficient patients, patients who used antibiotics in the previous six months, patients with orthodontic appliances or retainers and patients who previously had periodontal therapy or were in supportive therapy will be excluded from the study. A randomization plan based on sex (male; female), age (\</\> 50 years), nicotine exposure (smoker; non-smoker) and intervention (with/ without CHX) will be made using an online randomization software. All subjects will undergo a clinical examination before and 8 weeks after non-surgical periodontal therapy. Clinical examination will include all teeth except third molars and will be carried out using a millimeter graduated PCP-15 UNC periodontal probe (Hu-Friedy, Chicago, USA). The following periodontal indices will be measured: Full mouth plaque score (FMPS), Full mouth bleeding score (FMBS), Pocket probing depth (PPD), Clinical attachment level (CAL), Gingival recession (GR) and Tooth mobility (TM).

All subjects will have non-surgical periodontal therapy carried out according to the principles of Guided biofilm therapy (GBT) (EMS Dental, Geneve, Switzerland) using AIRFLOW Prophylaxis Master ultrasonic instruments (EMS Dental, Geneve, Switzerland) and Gracey curettes (Hu- Friedy, Chicago, USA). Moreover, half of the subjects in each group, 15 smokers and 15 non-smokers, will use a 0.12% chlorhexidine-digluconate based mouthwash (Curasept ADS 212, Curasept SpA, Saronno, Italy) twice a day for one minute during a period of 15 days. Subsequently, four subgroups of 15 subjects will be formed- non-smokers (NS), non-smokers who used CHX (NS-CHX), smokers (S) and smokers who used CHX (S-CHX).
PROBLEM TO BE SOLVED: To obtain the subject new gene group, a gene group in expression most abundantly among genes in expression in LPS-stimulated human monocytes, useful e.g. in diagnosing or treating various human diseases with human monocytes playing an important role therein. SOLUTION: This new gene group consists of high-ranking 50 genes in expression most abundantly among genes in expression in lipopolysaccharide(LPS)- stimulated human monocytes, wherein the cDNA for each of the genes has a base sequence of formula I to V or the like adjacent to the base sequence 5'-CATG-3' proximate to poly A region. This gene group is useful in e.g. developing new means for diagnosing or treating various human diseases with human monocytes playing an important role therein. This gene group is obtained by the following procedure: human monocytes are isolated according to a conventional method from healthy persons' venous blood and then cultured in an LPS- contg. medium followed by isolating RNA, from which high-ranking 50 genes in high-level expression determined by well-known SAGE analysis are selected in the order of expression frequency.
Background: Chronic obstructive pulmonary disease (COPD) is characterized by important extrapulmonary alterations that could affect the performance in dual task (DT) (motor and cognitive tasks executed simultaneously), which is defined as DT interference (DTI). Objective: To compare the performance of DT between individuals with COPD and healthy control subjects (HCSs). Methods: The literature search was conducted in seven databases (Medline, Scopus, Web of Science, PEDro, SciELO, LILACS, and Google Scholar) up to December 2023, including studies published in English, Spanish, or Portuguese. Studies with individuals diagnosed with COPD older than 60 years, who were evaluated with any DT assessment, and compared with HCS were included. The quality of the studies was evaluated using the risk of bias in nonrandomized studies of interventions (ROBINS-I). The meta-analysis was performed with JAMOVI software 5.4. The study protocol was registered on PROSPERO (CRD42023435212). Results: From a total of 128 articles, 5 observational studies were selected in this review, involving 252 individuals aged between 60 and 80 years, from France, Italy, Canada, Turkey, and Belgium. Notable DTI was observed in individuals with COPD compared to HCS (standard mean difference [SMD] = 0.91; 95% confidence interval (CI) 0.06-1.75, p = 0.04). Individuals with COPD had impaired gait speed, balance control, muscle strength, and cognitive interference during DT compared to HCS. DT assessment protocols included different combination of motor and cognitive tasks, using functional test, gait analysis, and muscle strength paired with countdown and verbal fluency tasks. Studies presented low (n = 2), moderate (n = 1), and serious (n = 2) overall risk of bias. Conclusion: Older adults diagnosed with COPD exhibited a significant DTI compared to HCSs, which is characterized by poorer physical and cognitive performance during DT execution. These findings highlight the importance of incorporating DT assessments into clinical practice for individuals with COPD.
In the treatment crossover period, participants will receive MK-3475A SC followed by pembrolizumab IV. After completion of the treatment crossover period, participants will enter the treatment continuation period, where they will receive their preferred intervention for up to \~1 year for renal cell carcinoma (RCC) and melanoma and for up to \~2 years for non-small cell lung cancer (NSCLC).
Participants in the Wait List Control will be offered the program after a 3-month wait period. While waiting for the program, participants are offered to attend monthly sessions on various wellness and prevention topics.
Participants receive positive affect intervention (weekly reminders to use gratitude, self-affirmations, parental affirmations) by phone. Participants receive small gifts in the mail every 2 weeks for 8 weeks. educational materials in the mail every 2 weeks for 8 weeks.
After selecting the study cases, the pupil size in both photopic and scotopic conditions and iris color(based on Simionescu's classification) will be recorded. Uncorrected distance visual acuity(UCDVA) will be measured by Snellen chart. Then the appropriate glasses will be placed according to the person's refraction and the corrected distance visual acuity(BCDVA) will be measured. Without changing the fitted glasses, corrected near visual acuity(BCNVA) is measured from a distance of 40 cm by the standard near vision chart (Rosenbaum near vision card). After this stage, one drop of pilocarpine 1% is prescribed in the patient's eye and 20 minutes later, the corrected near and far visual acuity is measured again. Thirty minutes and 8 hours after the administration of pilocarpine drop, the side effects of the drug, including headache, eye pain, eye redness, eye irritation, tearing, and blurred vision at night, are checked.
Patients will have regularly scheduled study visits on days 1, 8, and 15 of each cycle. On Day 1 patients will receive odetiglucan and CDX-1140. On Days 8 \& 15 only odetiglucan. Additional study visits may be required during some cycles for safety, efficacy, and translational assessments. Patients will dose to confirmed progression, a safety event or other administrative reason requiring discontinuation; all patients are allowed to dose up to 2 years (patients continuing to derive benefit may stay on treatment longer following consultation between Investigator and Sponsor). Following discontinuation patients will be followed up to 1 year.
INTRODUCTION: Background: Premenstrual syndrome (PMS) is a common disorder among female population that adversely affects their physical and emotional well-being. Conventional treatments for PMS may have limitations and side effects, prompting a need for complementary therapeutic approaches. This double-blind, randomized, placebo-controlled trial aimed to investigate the efficacy of individualized Homeopathic medicines (IH) in treating PMS symptoms in comparison to placebo (PL).
METHODS: This study recruited female participants of reproductive age who had been experiencing premenstrual syndrome (PMS) for >3 months, from the Outpatient Department. The participants were randomly assigned to receive either IH or PL. The measured outcomes included the Shortened Premenstrual Assessment Form (SPAF) questionnaire as the primary outcome, and the Premenstrual Tension Syndrome Visual Analogue Scale (PMTS-VAS) and the Premenstrual Tension Syndrome Observer Rating Scale - Revised (PMTS-OR) as secondary outcomes. These measures were assessed at baseline and every month for 3 months.
RESULTS: The results showed a statistically significant reduction in total SPAF scores for the IH group compared to the placebo group (F = 11.340; P < 0.001) at month 2 (-5.5 ± 1.8, P = 0.003), and month 3 (-6.6 ± 2.0, P = 0.002). Additionally, there were significant reductions in PMTS-VAS and PMTS-OR scores in the IH compared to placebo group. Natrum muriaticum (n = 4/30, 13.3 %) was the most frequently indicated medicines in the study. Four adverse events (13.33 %) occurred in the IH group, and six adverse events (16.67 %) in the Placebo group, with no serious events reported, and no additional medicinal treatment was required for participants during the study period.
CONCLUSIONS: Individualized Homeopathic medicines were found to be significantly effective, compared to placebo in reducing PMS symptoms. Further independent replication is warranted to validate and corroborate these findings, as well as to identify the most effective Homeopathic medicines for treating PMS symptoms. Until then, clinicians may consider these findings when exploring personalized and holistic therapeutic strategies for managing PMS.
TRIAL REGISTRATION: CTRI/2020/11/028,796, dt. 02/11/2020.
CONTEXT: Sport-related dystonia is a rare form of activity-specific dystonia that can severely impair an athlete's ability to perform. Due to a lack of data on the condition, it is difficult to diagnose and often overlooked, and no gold standard treatment has yet been defined.
CASE PRESENTATION: We present a rare and challenging case of sport-related dystonia that affected a 24-year-old male professional soccer player. The patient presented with severe rigidity and dystonia of the right lower-extremity, particularly the ankle and foot. The symptoms set on >1 year prior to the presentation to our outpatient clinic. He began to complain of stiffness and difficulty moving his lower limbs, especially his right leg, initially when playing soccer, but then also when walking normally. On presentation, he was unable to run and walked with difficulty, supporting his body weight only on the outside of his right foot. He also reported a motor trick and reverse motor trick involving the oral musculature in order to move his lower limb more freely.
MANAGEMENT AND OUTCOMES: An integrated rehabilitation approach based on postural rehabilitation, neuromuscular rehabilitation, and dental intervention was used to successfully treat this condition. The approach included: (1) postural rehabilitation with the Mézières-Bertelè method to reduce muscular stiffness, (2) neuromuscular re-education with Tai Chi exercises and electromyography-guided biofeedback, and (3) dental intervention and swallowing rehabilitation to limit impaired oral habits (due to the relationship between his impaired lower limb movements and motor tricks of the oral musculature). After 7 months of integrated rehabilitation, the patient returned to professional soccer.
CONCLUSIONS: This case report highlights the potential efficacy of an integrative rehabilitation approach for sports dystonia, particularly in cases where traditional treatments may not be effective. Such an approach could be considered a valuable option in the management of this rare, but debilitating, condition in athletes. Further research is needed to assess the effectiveness of this approach in larger populations.
TIME-A is a longitudinal research initiative. Anyone who has ever taken an Index test registered through Elysium Health is eligible to participate. Participation involves answering questions that will be administered via a survey format. Research participants' survey responses will be combined with their epigenetic Index data with the primary aim of identifying the contributions of 1) environmental and lifestyle factors, 2) general health, and 3) medical history, on biological age. Exploratory aims include the development of epigenetic signatures that are predictive of health status, and exploring the relationship between epigenetically-derived health phenotypes and biological age. These findings will lay the foundation for personalized health recommendations using Index (including, but not limited to: workout routines, diets, supplement regimens, medications, lifestyle changes).
OBJECTIVES: We assessed the impact of the COVID-19 pandemic on social determinants of health, mental health, substance use, and access to mental health and harm reduction services among key populations disproportionately impacted by sexually transmitted and blood-borne infections (STBBI).
METHODS: Online surveys (2021‒2022) were conducted in Canada among people who use drugs or alcohol (PWUD); African, Caribbean, and Black people (ACB); and First Nations, Inuit, and Métis peoples (FNIM). Descriptive analyses were conducted on social determinants of health, substance use, and access to services, stratified by changes in mental health status since the start of the pandemic.
RESULTS: A total of 3773 participants (1034 PWUD, 1556 ACB, and 1183 FNIM) completed the surveys, with 45.6% reporting a major/moderate impact of the pandemic on their ability to pay bills and 53% experiencing food insecurity since the start of the pandemic. Half (49.4%) of participants reported deteriorating mental health. A higher increase in substance use and related behaviours was seen in those with worsening mental health. Among those using substances, two thirds (69.4%) of those with worsening mental health reported increasing their use of substances alone, compared to 46.9% of those with better/similar mental health. Access to mental health and harm reduction services was low.
CONCLUSION: These intersecting health issues are among the risk factors for STBBI acquisition and act as barriers to care. Equitable interventions and policies addressing downstream and upstream determinants of health, with meaningful and sustainable leadership from key populations, may improve their health and well-being, to lower STBBI impact and improve future pandemic responses.
Optic neuritis is a rare presentation of vitamin B12 deficiency. We describe a 33-year-old female patient living with HIV presenting with progressive loss of vision for 1 week. She had a history of severe peripheral neuropathy that was managed with vitamin B12-containing tablets approximately three years before presenting with progressive loss of vision. On examination, she had no perception of light in the left eye and no perception of hand motion in the right eye. The fundus in her left eye had mild blurring of disc margins. Results from tests done showed a haemoglobin of 12.9g/dl, MCV 101fl, a serum vitamin B12 of 78pmol/l, and cytomegalovirus (CMV) test showed no active disease. She was diagnosed with optic neuritis and started on 30 mg tablets of prednisolone for 1 week with slight improvement. She was then started on vitamin B12 injections 1 mg daily for 10 days and thereafter, monthly for 6 months. She reported gradual improvement and regained her sight after 5 months treatment of with Vitamin B12 injections. Ophthalmic manifestations of vitamin B12 deficiency are not common and may present without haematological signs therefore, a high index of suspicion is required for early diagnosis and management of vitamin B12 deficiency.
PROBLEM TO BE SOLVED: To obtain a skin preparation for external use capable of keeping an antimicrobial activities for a long period without using an antimicrobial agent or a preservative providing a fear of causing injury to human body by including an extract of a specific plant as an antimicrobial component. SOLUTION: The objective skin preparation for external use is obtained by including an extract of Melissa officinalis, especially the extract by a polar solvent (e.g. water and ethanol) as an antimicrobial component. Especially effective antimicrobial activities are obtained when the polar solvent such as ethanol, 1,3-butylene glycol and an aqueous solution thereof are used. A surfactant can be added for enhancing the extraction efficiency. The formulating amount of the extract of the Melissa officinalis in the preparation for the external use such as a drug, a guasi-drug, cosmetics, etc., as an active ingredient is preferably within a concentration range of 0.001-20wt.% from the points of the effect, and the perfume and color when being added.
FIELD: pharmaceutical industry, pharmacy. SUBSTANCE: invention relates to medicinal agents used for prophylaxis, relieve or treatment of pathological states by disruption of parasitic organisms by means of chemical effect on their physiology. Invention relates to the development of solid pharmaceutical composition containing erythromycin base as an active substance that is mixed with potato starch, low-molecular polyvinylpyrrolidone, Tween-80 and talk. Method of its preparing involves wetting granulation, drying, dry granulation and calcium stearate, dry starch and talk are used for powdering. Starch sizing is used as wetting agent. Invention provides preparing medicinal preparation of high quality that retains its effect before intestine tract and protects stomach mucosa. Also, solid pharmaceutical composition shows suitable form for application of film cover and oral intake by patients being from newborns to adults. EFFECT: improved method of preparing, valuable properties of composition. 14 cl
<P>PROBLEM TO BE SOLVED: To provide a medical report capable of exactly convey an intention of a creator to a viewing person even if a plurality of findings are included in a medical report.  <P>SOLUTION: A report editor screen 47 of a medical report system has entry areas 47a, 47b for entering a plurality of findings. Each entry area 47a, 47b is provided with check boxes 57 for inputting evaluation values of subjective evaluation to the findings by the creator by every finding. Evaluation items of the subjective evaluation have importance indicating that the evaluation items are important matters which the creator desires to preferentially convey them to the viewing person, and when the check boxes 57 are turned on, the importance of the evaluation value of the finding is set as "high". The evaluation values are set per finding. In a report display screen for displaying a report in which the evaluation values are set, a display format is determined according to the evaluation values so that a display order of the finding with a high evaluation value become a high order.  <P>COPYRIGHT: (C)2010,JPO&INPIT
Participants received ASP1650 dose level 1 as intravenous infusion, every two weeks (Q2W) starting on Cycle 1 Day 1(C1D1) for up to a maximum of 12 cycles, or until disease progression, toxicity requiring study treatment cessation, start of another anticancer treatment, or until study discontinuation criteria was met, whichever occurred earlier. Duration of each treatment cycle was 14 days.
The endocannabinoid system (ECS) is a complex cell-signaling system that is responsible for maintaining homeostasis by modulating various regulatory reactions in response to internal and environmental changes. The influence of ECS on appetite regulation has been a subject of much recent research, however, the full extent of its impact remains unknown. Current evidence links human obesity to ECS activation, increased endocannabinoid levels in both central and peripheral tissues, along with cannabinoid receptor type 1 (CBR1) up-regulation. These findings imply the potential pharmacological use of the ECS in the treatment of obesity. Here, we present various pathophysiological processes in obesity involving the ECS, highlighting different pharmacological options for modulating endocannabinoid activity to treat obesity. However, the potential of those pharmacological possibilities remains under investigation and requires further research.
Randomization to 2 treatment groups. One group receives adjuvant treatment with D-cycloserine, up to 1 g/day. The second group receives adjuvant treatment with placebo, up to 1 g/day.